Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ICRF 154

Known as: ICRF-154 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
A Three-Dimensional Quantitative Structure-Activity Analysis of a New Class of Bisphenol Topoisomerase IIα Inhibitors
After the identification of a new lead bisphenol compound that had good topoisomerase IIα (EC 5.99.1.3) inhibitory activity, a… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2006
2006
A Three-Dimensional Quantitative Structure-Activity Relationship Study of the Inhibition of the ATPase Activity and the Strand Passing Catalytic Activity of Topoisomerase IIα by Substituted Purine…
Based on the topoisomerase IIα catalytic inhibitory activity of a previous hit compound, NSC35866, we screened 40 substituted… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.
The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
2000
2000
Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity.
This study investigates the solution thermodynamics of the iron complexes of dexrazoxane (ICRF-187, (+)-1,2-bis(3,5… Expand
1997
1997
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
A Chinese hamster ovary (CHO) cell line highly resistant to the non-cleavable complex-forming topoisomerase II inhibitor… Expand
1997
1997
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines
Histologic and biochemical studies were carried out to compare the protective activity of various bisdiketopiperazines against… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1995
Highly Cited
1995
A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane).
A series of twelve structurally related bisdioxopiperazines that included ICRF-187 (dexrazoxane), ICRF-159 (razoxane), ICRF-193… Expand
1992
1992
The effects of ICRF-154 in combination with other anticancer agents in vitro.
We studied the effects of ICRF-154 in combination with 11 anticancer agents on four human leukaemia cell lines. Cells were… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1991
Highly Cited
1991
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Several recently developed derivatives of bis(2,6-dioxopiperazine) have been shown to be new antitumor agents and are currently… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1991
Highly Cited
1991
Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
In the accompanying paper (K. Tanabe, Y. Ikegami, R. Ishida, and T. Andoh, Cancer Res., 51: 4903-4908, 1991), we showed that ICRF… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE